drugset / Trial / NCT00501267

A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder

NCT00501267

Phase 1 Completed 24 enrolled GlaxoSmithKline
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to determine the effect of repeat doses of solabegron and oxybutynin when taken alone or together

Timeline

Start
2007-06
Primary completion
2007-08
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxybutynin Small molecule
Subject Solabegron Unknown

Indications